19-11105307-G-A
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000527.5(LDLR):c.401G>A(p.Cys134Tyr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. C134F) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000527.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LDLR | NM_000527.5 | c.401G>A | p.Cys134Tyr | missense_variant | 4/18 | ENST00000558518.6 | NP_000518.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LDLR | ENST00000558518.6 | c.401G>A | p.Cys134Tyr | missense_variant | 4/18 | 1 | NM_000527.5 | ENSP00000454071 | P3 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Hypercholesterolemia, familial, 1 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | literature only | LDLR-LOVD, British Heart Foundation | Mar 25, 2016 | - - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 27, 2023 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Identified in a family with hypercholesterolemia in published literature (Bertolini et al., 2013); This variant is associated with the following publications: (PMID: 2988123, 12459547, 23375686) - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 07, 2020 | The p.C134Y pathogenic mutation (also known as c.401G>A), located in coding exon 4 of the LDLR gene, results from a G to A substitution at nucleotide position 401. The cysteine at codon 134 is replaced by tyrosine, an amino acid with highly dissimilar properties, and is located in the ligand binding 3 domain. This alteration has been detected in an individual from an autosomal dominant hypercholesterolemia cohort (Bertolini S et al. Atherosclerosis. 2013;227:342-8). Internal structural analysis indicates this alteration would disrupt a disulfide bond needed for proper protein function (Mayhew Mn et al. Protein Eng. 1992;5(6):489-94; Daly NL et al. Proc Natl Acad Sci USA. 1995;92(14):6334-8; Fisher C et al. Mol Cell. 2006;22(2):277-83). In addition, other alterations at the same amino acid position, C134F, C134R and C134W, have also been detected in individuals from familial hypercholesterolemia cohorts (Lombardi MP et al. Clin Genet. 2000;57:116-24; Bertolini S et al. Arterioscler. Thromb Vasc Biol. 2000;20:E41-52). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Familial hypercholesterolemia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 28, 2023 | This missense change has been observed in individuals with familial hypercholesterolemia (PMID: 23375686, 26081744). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Cys134 amino acid residue in LDLR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10735632, 10978268, 11462246, 12730724, 18718593, 25921077). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. This variant affects a cysteine residue located within an LDLRA or epidermal-growth-factor (EGF)-like domains of the LDLR protein. Cysteine residues in these domains have been shown to be involved in the formation of disulfide bridges, which are critical for protein structure and stability (PMID: 7548065, 7603991, 7979249). In addition, missense substitutions within the LDLRA and EGF-like domains affecting cysteine residues are overrepresented among patients with hypercholesterolemia (PMID: 18325082). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LDLR protein function. ClinVar contains an entry for this variant (Variation ID: 251203). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces cysteine, which is neutral and slightly polar, with tyrosine, which is neutral and polar, at codon 134 of the LDLR protein (p.Cys134Tyr). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at